Phaseline

Companies › Suzhou HepaThera Biotech

Suzhou HepaThera Biotech: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HT-101–Phase 2Chronic Hepatitis BFeb 2027
HT-102–Phase 2Chronic Hepatitis BFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07245953HT-101Phase 2Chronic Hepatitis BInfectious diseaseFeb 2027
NCT07245953HT-102Phase 2Chronic Hepatitis BInfectious diseaseFeb 2027
NCT07183306HT-101Phase 1Chronic Hepatitis BInfectious diseaseAug 2027
NCT07183306HT-102Phase 1Chronic Hepatitis BInfectious diseaseAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

TaiMed Biologics Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.